SEARCH

Current Edition

Alzheimer

Biogen CEO to step down as company pulls back from Alzheimer’s drug

Biogen is searching for a new CEO along with additional ways to cut costs after another quarter of paltry sales for its closely watched Alzheimer’s …

Continue Reading →
Aduhelm

Biogen, having scrapped Aduhelm, tries to convince investors of turnaround plan

Biogen’s drug for Alzheimer’s disease, once considered a blockbuster-in-waiting, has run into so many obstacles since gaining approval last June that the company is now …

Continue Reading →
Aduhelm

Biogen pulls European application for Aduhelm in another setback for the Alzheimer’s drug

Dive Brief: Biogen has withdrawn a request to start selling its Alzheimer’s disease drug in Europe, marking the latest setback in the company’s efforts to …

Continue Reading →
Alzheimer

Medicare finalizes policy limiting coverage of Biogen Alzheimer’s drug

Medicare will not pay for Biogen’s new Alzheimer’s medicine unless prospective patients are enrolled in a clinical trial, the U.S. government said Thursday in a …

Continue Reading →
Alzheimer

Biogen, struggling to sell Alzheimer’s drug, begins layoffs to save money

Biogen has begun to lay off employees as part of a previously disclosed effort to lower annual expenses by half a billion dollars. The move comes …

Continue Reading →
Biogen

Sage claims new data show depression drug works, but doubts remain

Dive Brief: An experimental, fast-acting depression drug from Sage Therapeutics and partner Biogen met its main goals in a closely watched Phase 3 study that …

Continue Reading →
Al Sandrock

Al Sandrock, former top Biogen scientist, to join drug discovery startup’s board

Dive Brief: Al Sandrock, a former top Biogen executive who led development of the company’s Alzheimer’s drug Aduhelm, is joining the board of directors at …

Continue Reading →
Alzheimer

Biogen’s Alzheimer’s drug sales remain slow as company warns of further cost cuts

Biogen recorded $1 million in revenue from its new treatment for Alzheimer’s disease in the last quarter of 2021, offering the latest evidence that the …

Continue Reading →
Alzheimer

Medicare proposes to limit coverage of Biogen Alzheimer’s drug

Medicare will restrict coverage of Biogen’s controversial Alzheimer’s treatment only to patients who take part in a rigorous clinical trial, the federal government announced Tuesday, …

Continue Reading →
Aduhelm

Biogen reserves four years for trial meant to confirm its Alzheimer’s drug works

A crucial study evaluating Biogen’s approved drug for Alzheimer’s disease is set to begin in May, the company disclosed Thursday, and if enrollment goes as …

Continue Reading →
Aduhelm

Biogen seeking more information in investigation of Aduhelm patient’s death

Aduhelm has come under intense scrutiny since the Food and Drug Administration’s controversial June approval of the drug, the first new Alzheimer’s treatment in decades …

Continue Reading →
Aduhelm

With approval plans underway, Lilly’s next move is to test its Alzheimer’s drug against Biogen’s

With few treatment options and millions of patients in the U.S. alone, Alzheimer’s has long been one of the biggest targets for drug developers. Yet, …

Continue Reading →
ALS

Biogen’s closely watched ALS drug comes up short in late-stage study

An experimental drug for amyotrophic lateral sclerosis missed the main goal of a late-stage clinical trial, marking another setback in attempts to treat the debilitating …

Continue Reading →
Alzheimer

Hint of benefit in Alzheimer’s drug study fuel stock surge for Swiss biotech

A small clinical trial of a once-failed Alzheimer’s drug offered tantalizing but inconclusive hints of benefit, propelling shares in its biotech maker higher by more …

Continue Reading →
Aduhelm

Lilly, preparing Alzheimer’s drug plans, forms new neuroscience unit in company restructure

After numerous setbacks in Alzheimer’s disease, Lilly has high hopes for a breakthrough with donanemab. When the FDA controversially approved Biogen’s Aduhelm in June, it …

Continue Reading →
Aduhelm

HHS watchdog to review FDA accelerated approval process after Aduhelm controversy

The U.S. health department’s inspector general will review how the Food and Drug Administration grants accelerated approvals of new drugs, announcing a broad investigation Wednesday …

Continue Reading →